Salarius Pharmaceuticals Inc(SLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLRX Salarius Pharmaceuticals Inc

Trading 01-02 15:43:32 EST

0.6700

+0.0212

+3.27%

High0.6700	Low0.6411	Vol249.23K
Open0.6488	D1 Closing0.6488	Amplitude4.45%
Mkt Cap3.93M	Tradable Cap2.39M	Total Shares5.86M
T/O165.83K	T/O Rate6.99%	Tradable Shares3.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLRX","market":"US","secType":"STK","nameCN":"Salarius Pharmaceuticals Inc","latestPrice":0.67,"timestamp":1767386497934,"preClose":0.6488,"halted":0,"volume":249234,"delay":0,"floatShares":3565400,"shares":5862178,"eps":-39.1909,"marketStatus":"Trading","change":0.0212,"latestTime":"01-02 15:43:32 EST","open":0.6488,"high":0.67,"low":0.6411,"amount":165828.71421900002,"amplitude":0.044544,"askPrice":0.6746,"askSize":200,"bidPrice":0.6699,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":-39.1909,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1767387600000},"marketStatusCode":2,"adr":0,"listingDate":1422507600000,"exchange":"NASDAQ","adjPreClose":0.6488,"preHourTrading":{"tag":"盘前","latestPrice":0.6475,"preClose":0.6488,"latestTime":"09:13 EST","volume":2042,"amount":1317.0426256,"timestamp":1767363238215},"postHourTrading":{"tag":"盘后","latestPrice":0.64,"preClose":0.6488,"latestTime":"18:58 EST","volume":5336,"amount":3434.0561,"timestamp":1767225484891},"volumeRatio":1.938464},"requestUrl":"/m/hq/s/SLRX/tweets","defaultTab":"tweets","newsList":[{"id":"2592019681","title":"Press Release: Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2592019681","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592019681?lang=en_us&edition=fundamental","pubTime":"2025-12-20 00:12","pubTimestamp":1766160720,"startTime":"0","endTime":"0","summary":"HOUSTON, Dec. 19, 2025  -- Salarius Pharmaceuticals, Inc.   today announced that its 2025 Annual Meeting of Stockholders  scheduled for and convened on December 19, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission  on November 7, 2025.The record date for determination of stockholders entitled to vote at the reconvened Annual Meeting remains the close of business on October 24, 2025. At the time the Annual Meeting was adjourned, proxies had been submitted by stockholders representing approximately 30% of the shares of the Company's common stock issued and outstanding as of the record date.The Company, its directors, certain of its officers, and other employees are or will be \"participants\"  in the solicitation of proxies from the Company's stockholders in connection with the matters to be considered at the Annu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4134","BK4099","BK4555","BK4585","BK4588","III","03160","BK4604","SLRX","TM"],"gpt_icon":0},{"id":"2592905442","title":"Salarius Pharmaceuticals Rebrands as Decoy Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2592905442","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592905442?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:50","pubTimestamp":1766062216,"startTime":"0","endTime":"0","summary":"Salarius Pharmaceuticals Inc. announced plans to change its corporate name to Decoy Therapeutics Inc. and update its NASDAQ ticker symbol to DCOY, reflecting its strategic shift toward novel peptide-conjugate therapeutics for viral diseases and oncology. The move follows the company’s combination with Decoy Therapeutics Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL6b4tjB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NDAQ","SG9999014039.USD","IE00BKPKM429.USD","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014013.SGD","BK4112","BK4585","BK4139","IE00B64PRP62.GBP","LU2210149790.SGD","LU0314104364.USD","SG9999014005.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","SLRX"],"gpt_icon":0},{"id":"2592192905","title":"Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2592192905","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592192905?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:50","pubTimestamp":1766062200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA8BD6VG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLRX","BK4139"],"gpt_icon":0},{"id":"2588443775","title":"Salarius Pharmaceuticals' Decoy Unit Partners With Texas Biomed on Flu Inhibitor Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588443775","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588443775?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:38","pubTimestamp":1764599928,"startTime":"0","endTime":"0","summary":"Salarius Pharmaceuticals  said Monday its unit Decoy Therapeutics and the Texas Biomedical Research Institute are partnering to run in vitro testing of Decoy's influenza inhibitors, including those targeting H5N1 avian flu.Financial terms weren't provided.Salarius said the partnership follows its recent underwritten public offering that raised $8 million and consumated a previously announced merger with Decoy Therapeutics, and is expected to support plans to advance Decoy's antiviral pipeline.Decoy expects to move its lead pan-coronavirus program toward an Investigational New Drug Application filing with the US Food and Drug Administration in the next year, Salarius said.Shares of the company were down 0.5% in recent early Monday trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SLRX"],"gpt_icon":0},{"id":"2588778847","title":"BRIEF-Salarius Pharmaceuticals To Collaborate With Texas Biomedical Research Institute On Avian Flu Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2588778847","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588778847?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:26","pubTimestamp":1764595589,"startTime":"0","endTime":"0","summary":"BRIEF-Salarius Pharmaceuticals To Collaborate With Texas Biomedical Research Institute On Avian Flu StudyDec 1 (Reuters) - Salarius Pharmaceuticals Inc SLRX.O:SALARIUS PHARMACEUTICALS TO COLLABORATE W","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2R5JHN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRX","BK4139"],"gpt_icon":0},{"id":"2588720880","title":"Salarius Pharmaceuticals to Collaborate With Texas Biomedical Research Institute on Avian Flu Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720880","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588720880?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:00","pubTimestamp":1764594005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2R5JHN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLRX"],"gpt_icon":0},{"id":"2586413325","title":"Salarius Pharmaceuticals Director Arnold C. Hanish Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586413325","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586413325?lang=en_us&edition=fundamental","pubTime":"2025-11-25 06:08","pubTimestamp":1764022119,"startTime":"0","endTime":"0","summary":"Arnold C. Hanish, Director, reported the acquisition of common shares of Salarius Pharmaceuticals Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL2Xksh0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Salarius Pharmaceuticals Director Arnold C. Hanish Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLRX"],"gpt_icon":0},{"id":"2586496450","title":"Salarius Pharmaceuticals Files Initial Beneficial Ownership Statement for CEO Frederick II Pierce","url":"https://stock-news.laohu8.com/highlight/detail?id=2586496450","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586496450?lang=en_us&edition=fundamental","pubTime":"2025-11-25 00:23","pubTimestamp":1764001437,"startTime":"0","endTime":"0","summary":"Salarius Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing names Frederick II Pierce as the beneficial owner, who serves as the Chief Executive Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL9pR4TZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRX","BK4139"],"gpt_icon":0},{"id":"2585168566","title":"Salarius Pharmaceuticals CFO Mark J. Rosenblum Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585168566","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585168566?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:42","pubTimestamp":1763674977,"startTime":"0","endTime":"0","summary":"Mark J. Rosenblum, Executive Vice President of Finance and Chief Financial Officer of Salarius Pharmaceuticals Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 20, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL9T2X6w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Salarius Pharmaceuticals CFO Mark J. Rosenblum Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLRX"],"gpt_icon":0},{"id":"2584769119","title":"BRIEF-Salarius Pharmaceuticals Inc - Frederick E. Pierce To Serve As Chief Executive Officer - Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584769119","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584769119?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:39","pubTimestamp":1763588395,"startTime":"0","endTime":"0","summary":"BRIEF-Salarius Pharmaceuticals Inc - Frederick E. Pierce To Serve As Chief Executive Officer - FilingNov 19  - Salarius Pharmaceuticals Inc SLRX.O:SALARIUS PHARMACEUTICALS INC - FREDERICK E. PIERCE TO SERVE AS CHIEF EXECUTIVE OFFICER - FILINGFurther company coverage: SLRX.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV1ER:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRX","BK4139"],"gpt_icon":0},{"id":"2584197543","title":"Salarius Pharmaceuticals Inc - Frederick E. Pierce to Serve as Chief Executive Officer - Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584197543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584197543?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:15","pubTimestamp":1763586902,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV1ER:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLRX","BK4139"],"gpt_icon":0},{"id":"2584213978","title":"Salarius Pharmaceuticals Completes Merger With Decoy Therapeutics and Raises $8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584213978","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584213978?lang=en_us&edition=fundamental","pubTime":"2025-11-20 03:48","pubTimestamp":1763581738,"startTime":"0","endTime":"0","summary":"Salarius Pharmaceuticals has completed its previously announced merger with Decoy Therapeutics, combining the two companies to focus on advancing Decoy's pipeline of peptide conjugate therapeutics. Following the merger and a recent underwritten public offering that raised $8 million in gross proceeds, the combined company has pro forma cash of approximately $14 million and approximately 5.9 million shares of common stock outstanding. Salarius stated that its shares continue to trade on the Nasdaq Stock Market under the ticker symbol \"SLRX.\" The company is prioritizing the development of Decoy's lead asset, a pan-coronavirus antiviral, with plans to submit an IND application to the FDA within the next 12 months, and is also progressing other programs targeting flu, COVID-19, RSV, and gastrointestinal cancers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL2wNMCY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLRX"],"gpt_icon":0},{"id":"2584978214","title":"Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”","url":"https://stock-news.laohu8.com/highlight/detail?id=2584978214","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584978214?lang=en_us&edition=fundamental","pubTime":"2025-11-20 03:42","pubTimestamp":1763581320,"startTime":"0","endTime":"0","summary":"Company has pro forma cash of approximately $14 million following recent public offeringHOUSTON and CAMBRIDGE, Mass., Nov.  19, 2025  (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/19/3191374/0/en/Salarius-Pharmaceuticals-Cites-Errors-on-S-P-CapIQ-Platform-Following-Merger-with-Decoy-Therapeutics-Affirms-Its-Shares-Continue-to-Trade-on-the-Nasdaq-Stock-Market-Under-the-Symbo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","LENZ","QID","USJW.SI","BK4539","SQQQ","TSYW.SI","SLRX","USAW.SI","PSQ","TQQQ",".IXIC","NVIW.SI","QLD","NQmain","BK4007","BK4139"],"gpt_icon":1},{"id":"2584367706","title":"Salarius Pharmaceuticals - Became Aware That Certain Financial Market Data Platforms Published That Co Had Been Delisted From Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2584367706","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584367706?lang=en_us&edition=fundamental","pubTime":"2025-11-18 06:38","pubTimestamp":1763419125,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WT1QM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLRX","BK4139"],"gpt_icon":0},{"id":"2583959959","title":"BUZZ-Salarius jumps after completing merger with Decoy Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2583959959","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583959959?lang=en_us&edition=fundamental","pubTime":"2025-11-13 22:38","pubTimestamp":1763044683,"startTime":"0","endTime":"0","summary":"BUZZ-Salarius jumps after completing merger with Decoy Therapeutics** Shares of drug developer Salarius Pharmaceuticals SLRX.O rise 17.3% to $1.22 in early trading ** Co and Decoy Therapeutics complete their merger, combining resources to accelerate development of peptide-based drugs for serious diseases - SLRX** The merged co is renamed Decoy Therapeutics and focuses on advancing Decoy's pipeline, which includes treatments for respiratory infections and gastrointestinal cancers, co says** SLRX says Frederick \"Rick\" Pierce, Decoy's co-founder, serves as chief executive officer** Decoy's technology uses artificial intelligence and rapid manufacturing techniques to design and produce drug candidates quickly - SLRX** Decoy secures funding from institutional investors and programs run by Massachusetts Life Sciences, Google, NVIDIA, and Johnson & Johnson** Including session's move, stock down ~94% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL4N3WP13P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0792757196.USD","NVDS","IE00BJT1NW94.SGD","NVD","LU0557290698.USD","IE00BQXX3D17.EUR","3NVD.UK","HK0000306685.HKD","LU0345768153.USD","LU0127658192.USD","LU1066051498.USD","LU1934455277.USD","SG9999001440.SGD","HK0000306701.USD","LU0784385170.HKD","LU0784385840.USD","NVD2.UK","LU2089984988.USD","NVDX","SG9999015978.USD","IE00BQXX3C00.GBP","SNVD.UK","LU1861127337.USD","LU0058720904.USD","SLRX","JNJ","NVIW.SI","BK4548","BK4543","LU0276348264.USD","NVD3.UK","LU1894683348.USD","LU2452424414.USD","2NVD.UK","BK4549","LU1935043536.SGD","LU0057025933.USD","NVDD","IE00B19Z3B42.SGD","BK4592","NVDY","NVDS.UK","NVDU","LU0265550359.USD","IE00BQXX3F31.USD","LU1815336760.USD","BK4514"],"gpt_icon":1},{"id":"2583159378","title":"Press Release: Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2583159378","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583159378?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:45","pubTimestamp":1763041500,"startTime":"0","endTime":"0","summary":"Strategic transaction supports the advancement of Decoy's rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP ACT platform. Combined company has pro forma cash of $14 million following merger and closing of recent public offering. HOUSTON and CAMBRIDGE, Mass., Nov. 13, 2025  -- Salarius Pharmaceuticals   and Decoy Therapeutics  announce the completion of their strategic merger with the combined company now focused on advancing Decoy's pipeline of peptide conjugate therapeutics engineered through its IMP ACT platform that reduces the complexity of drug development and manufacturing.Then new company will be renamed Decoy Therapeutics. In addition to Decoy's Co-founder Mr. Pierce serving as Chief Executive Officer, the new company is led by Decoy's Co-founder Chief Scientific Officer Barbara Hibner, by Decoy's Chief Business Officer Peter Marschel, by Decoy's Chief Technology Officer Mike Lipp and by Decoy's acting Chief Medical Office","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4604","SLRX","LENZ","BK4555","BK4539","BK4585","BK4588","BK4099","BK4007","TM","BK4139"],"gpt_icon":0},{"id":"2583267306","title":"Crude Oil Dips 4%; On Holding Shares Jump After Q3 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2583267306","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583267306?lang=en_us&edition=fundamental","pubTime":"2025-11-13 01:18","pubTimestamp":1762967899,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/11/48811415/crude-oil-dips-4-on-holding-shares-jump-after-q3-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMCT","BK4194","BK4204","BK4585","USJW.SI","LU0472753341.HKD","LU0289739343.SGD","BK4223","BK4505","CYPH","VSA","ONON","BK4139","MNQmain","LU1804176565.USD","BK4561","USAW.SI","QID","LU0057025933.USD","SQQQ","LFS","LU0289961442.SGD","BK4563","NQmain","LPTX","TQQQ","BK4588","QLD","LU0069063385.USD",".IXIC","PSQ","NRGV","SLRX","NVIW.SI","BK4182","BK4146","BK4547","LU0511384066.AUD","LU2265009873.SGD","TSYW.SI"],"gpt_icon":1},{"id":"2582340140","title":"Shoulder Innovations (SI) Stock Rose 21% After-Hours: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2582340140","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582340140?lang=en_us&edition=fundamental","pubTime":"2025-11-12 15:33","pubTimestamp":1762932836,"startTime":"0","endTime":"0","summary":"Shoulder Innovations shares jumped more than 21% in after-hours trading Tuesday after the company posted strong quarterly results and raised its 2025 revenue forecast.\n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48795573/shoulder-innovations-si-stock-rose-21-after-hours-heres-why","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRX","BK4082","BK4204","SI","LFS","BK4139","BK4211"],"gpt_icon":0},{"id":"2582534699","title":"Why Did RYTHM (RYM) Stock Jump Over 23% Overnight?","url":"https://stock-news.laohu8.com/highlight/detail?id=2582534699","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582534699?lang=en_us&edition=fundamental","pubTime":"2025-11-12 13:15","pubTimestamp":1762924556,"startTime":"0","endTime":"0","summary":"RYTHM Inc. shares jumped 23.3% after hours following strong Q3 revenue growth and nationwide THC beverage expansion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48794703/why-did-rythm-rym-stock-jump-over-23-overnight","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4152","SLRX","BK4139","RYM"],"gpt_icon":0},{"id":"2582348289","title":"Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours?","url":"https://stock-news.laohu8.com/highlight/detail?id=2582348289","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582348289?lang=en_us&edition=fundamental","pubTime":"2025-11-12 11:31","pubTimestamp":1762918260,"startTime":"0","endTime":"0","summary":"Salarius Pharmaceuticals shares jumped 23.7% in after-hours trading Tuesday, closing at $1.21 following its public offering announcement.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/11/Display-Of-Quotes-Pricing-Graph-Visualiz.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/11/Display-Of-Quotes-Pricing-Graph-Visualiz.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/equities/25/11/48794182/why-did-salarius-slrx-shares-soar-over-23-after-hours","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48794182/why-did-salarius-slrx-shares-soar-over-23-after-hours","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["SLRX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.salariuspharma.com","stockEarnings":[{"period":"1week","weight":0.0201},{"period":"1month","weight":-0.2545},{"period":"3month","weight":-0.8437},{"period":"6month","weight":-0.9513},{"period":"1year","weight":-0.9765},{"period":"ytd","weight":-0.9765}],"compareEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.019},{"period":"6month","weight":0.0905},{"period":"1year","weight":0.1635},{"period":"ytd","weight":0.1635}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.016664},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.047904},{"month":3,"riseRate":0.454545,"avgChangeRate":0.000826},{"month":4,"riseRate":0.181818,"avgChangeRate":-0.073659},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.005048},{"month":6,"riseRate":0.545455,"avgChangeRate":-0.047064},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.136217},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.111993},{"month":9,"riseRate":0.090909,"avgChangeRate":-0.12638},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.128321},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.062226},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.07199}],"exchange":"NASDAQ","name":"Salarius Pharmaceuticals Inc","nameEN":"Salarius Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Salarius Pharmaceuticals Inc(SLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Salarius Pharmaceuticals Inc(SLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Salarius Pharmaceuticals Inc,SLRX,Salarius Pharmaceuticals Inc股票,Salarius Pharmaceuticals Inc股票老虎,Salarius Pharmaceuticals Inc股票老虎国际,Salarius Pharmaceuticals Inc行情,Salarius Pharmaceuticals Inc股票行情,Salarius Pharmaceuticals Inc股价,Salarius Pharmaceuticals Inc股市,Salarius Pharmaceuticals Inc股票价格,Salarius Pharmaceuticals Inc股票交易,Salarius Pharmaceuticals Inc股票购买,Salarius Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Salarius Pharmaceuticals Inc(SLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Salarius Pharmaceuticals Inc(SLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction